The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
Lanthanum carbonate is a phosphate binder used to reduce the intestinal absorption of phosphates. It was approved as a medication (Fosrenol®, Shire Pharmaceuticals) to absorb excess phosphate in cases of end-stage renal failure (ESRD).